Auhtors: Raffin C, Vo LT, Bluestone JA
PMID: 31811270 PMCID: PMC7814338 DOI: 10.1038/s41577-019-0232-6
Abstract
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In this Review, we discuss the biology of Treg cells and describe new efforts in Treg cell engineering to enhance specificity, stability, functional activity and delivery. Finally, we envision that the success of Treg cell therapy in autoimmunity and transplantation will encourage the clinical use of adoptive Treg cell therapy for non-immune diseases, such as neurological disorders and tissue repair.
Keywords: T regulatory cells, Treg, Treg cell therapies
Source: https://pubmed.ncbi.nlm.nih.gov/31811270/
Archive: https://archive.is/1XB98
